Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: A systematic review and meta-analysis

International Journal of Cancer

Volumn 135, Issue 9, 2014, Pages 2183-2190

  Lagergren, Katarina ^a   Lagergren, Jesper ^a,b   Brusselaers, Nele ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

exogenous oestrogen therapy; hormonal; oesophageal neoplasm; oestrogen

Indexed keywords

ARTICLE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; ESTROGEN THERAPY; EXPOSURE; HUMAN; META ANALYSIS; ORAL CONTRACEPTIVE USE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

EXOGENOUS OESTROGEN THERAPY; HORMONAL; OESOPHAGEAL NEOPLASM; OESTROGEN;

ADENOCARCINOMA; CONTRACEPTIVES, ORAL; ESOPHAGEAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PROGNOSIS; RISK FACTORS;

EID: 84906281447     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28869     Document Type: Article

References (44)

1. Edgren G, Adami HO, Weiderpass E, et al. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013; 62: 1406-14.
2. Lagergren J, Lagergren P,. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 2013; 63: 232-48.
3. Lofdahl HE, Lu Y, Lagergren J,. Sex-specific risk factor profile in oesophageal adenocarcinoma. Br J Cancer 2008; 99: 1506-10.
4. Forman D, Debacker G, Elder J, et al. Epidemiology of, and risk-factors for, helicobacter-pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993; 34: 1672-76.
5. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
6. Lagergren J, Bergstrom R, Nyren O,. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-90.
7. Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1399-1412.
8. Lagergren K, Mattsson F, Lagergren J,. Abdominal fat and male excess of esophageal adenocarcinoma. Epidemiology 2013; 24: 465-6.
9. Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009; 58: 16-23.
10. Rutegard M, Shore R, Lu YX, et al. Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer 2010; 46: 1093-100.
11. Bodelon C, Anderson GL, Rossing MA, et al. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) 2011; 4: 840-50.
12. Cronin-Fenton DP, Murray LJ, Whiteman DC, et al. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer 2010; 46: 2067-76.
13. Freedman ND, Lacey JV, Jr, Hollenbeck AR, et al. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer 2010; 116: 1572-81.
14. Lindblad M, Garcia Rodriguez LA, Chandanos E, et al. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006; 94: 136-41.
15. Yu H, Liu G, Zhao P, et al. Hormonal and reproductive factors and risk of esophageal cancer in Chinese postmenopausal women: a case-control study. Asian Pac J Cancer Prev 2011; 12: 1953-6.
16. Shuster LT, Rhodes DJ, Gostout BS, et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010; 65: 161-6.
17. Eden KJ, Wylie KR,. Quality of sexual life and menopause. Womens Health (Lond Engl) 2009; 5: 385-96.
18. Liang SY, Grossman D, Phillips KA,. User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives. Contraception 2012; 86: 666-72.
19. King J,. Contraception and lactation. J Midwifery Womens Health 2007; 52: 614-20.
20. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
21. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
23. Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007; 13: 1585-94.
24. Cheng KK, Sharp L, McKinney PA, et al A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000; 83: 127-32.
25. Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57: 173-80.
26. Corley DA, Kubo A, Zhao W,. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 352-58.
27. Green J, Czanner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 2012; 130: 2387-96.
28. Lagergren J, Lagergren P,. Oesophageal cancer. BMJ 2010; 341: c6280.
29. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.
30. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231: 1150-4.
31. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986; 320: 134-9.
32. Simpson E, Rubin G, Clyne C, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 2000; 11: 184-8.
33. Simpson ER, Clyne C, Speed C, et al. Tissue-specific estrogen biosynthesis and metabolism. Ann NY Acad Sci 2001; 949: 58-67.
34. Tiffin N, Suvarna SK, Trudgill NJ, et al. Sex hormone receptor immunohistochemistry staining in Barrett's oesophagus and adenocarcinoma. Histopathology 2003; 42: 95-6.
35. Akgun H, Lechago J, Younes M,. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus. Anticancer Res 2002; 22: 1459-61.
36. Liu L, Chirala M, Younes M,. Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res 2004; 24: 2919-24.
37. Kalayarasan R, Ananthakrishnan N, Kate V, et al. Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus 2008; 21: 298-303.
38. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998; 247: 75-8.
39. Kendall BJ, Macdonald GA, Hayward NK, et al. The risk of Barrett's esophagus associated with abdominal obesity in males and females. Int J Cancer 2013; 132: 2192-9.
40. Sukocheva OA, Wee C, Ansar A, et al. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells. Dis Esophagus 2013; 26: 628-35.
41. Nordenstedt H, Zheng ZL, Cameron AJ, et al. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology 2008; 134: 921-28.
42. Nilsson M, Johnsen R, Ye WM, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290: 66-72.
43. Nilsson M, Lundegardh G, Carling L, et al. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scand J Gastroenterol 2002; 37: 626-30.
44. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.